Interferon alpha (IFN-α) in systemic lupus erythematosus (SLE)
DOI:
https://doi.org/10.12775/JEHS.2023.13.01.008Keywords
systemic lupus erythematosus, interferon alphaAbstract
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology. An important role in the pathogenesis of SLE has been attributed to interferon alpha (IFN-α), which stimulates the expression of numerous genes, resulting in an increased autoinflammatory response. Recent studies have demonstrated increased levels of this cytokine in patients with SLE, as well as in relatives, indicating that IFN- α is an inherited risk factor for lupus. Cases of induction of SLE/lupus-like syndrome after IFN- α therapy also point to the involvement of interferon in the pathogenesis of the disease. Interferon being a probable initiator of the disease, as well as a marker to examine its exacerbations, is a potential research target to better understand the etiology and pathogenesis of lupus. More research is needed to determine the feasibility of using INF-blocking agents for new therapies in SLE.
References
Morrow WJW, Nelson L, Watts R, Isenberg DA. Autoimmune rheumatic disease. 2nd ed. Oxford: Oxford University Press, 1999.
Zoma A. Musculoskeletal involvement in systemic lupus erythematosus. Lupus. 2004;13:851–853, 10.1191/0961203303lu2021oa
Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011;6(4):330-336.
Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clinical Rheumatology. 2005;24(2):178–181. [PubMed] [Google Scholar], doi:10.1007/s10067-004-1024-2
Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis and Rheumatism. 2000;43(7):1431–1442, doi:10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979; 301:5–8., doi:10.1056/NEJM197907053010102
Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003;100:2610–2615. doi:10.1073/pnas.0337679100
Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8(6):492-502., doi:10.1038/sj.gene.6364408
Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491-1503., doi:10.1002/art.21031
Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64(12):1692-1697., doi:10.1136/ard.2004.033753
Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951-2962, doi:10.1002/art.22044
Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60(6):1785-1796, doi:10.1002/art.24557
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Sara Moqbil, Eryk Mikos, Joanna Dmochowska, Aleksandra Wójcik, Milena Leziak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 172
Number of citations: 0
